NYSE:ABBV - AbbVie Stock Price, Forecast & News

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie declared a -- dividend on Friday, November 1st. Investors of record on Wednesday, January 15th will be paid a dividend of $1.18 per share on Friday, February 14th. This represents a yield of 5.93%. The ex-dividend date is Tuesday, January 14th. This is an increase from AbbVie's previous -- dividend of $1.07. View AbbVie's Dividend History.

AbbVie declared that its board has approved a stock repurchase plan on Thursday, December 13th 2018, which authorizes the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to buy up to 3.8% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's management believes its stock is undervalued.

AbbVie Inc (NYSE:ABBV) posted its quarterly earnings data on Friday, November, 1st. The company reported $2.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.29 by $0.04. The company had revenue of $8.48 billion for the quarter, compared to analysts' expectations of $8.37 billion. AbbVie had a negative return on equity of 155.96% and a net margin of 9.90%. The business's revenue was up 3.0% compared to the same quarter last year. During the same period last year, the company earned $2.14 EPS. View AbbVie's Earnings History.

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, February 7th 2020. View Earnings Estimates for AbbVie.

AbbVie will be holding an earnings conference call on Friday, February 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

AbbVie issued an update on its FY19 earnings guidance on Friday, November, 1st. The company provided EPS guidance of $8.90-8.92 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.90.

13 equities research analysts have issued twelve-month price objectives for AbbVie's stock. Their forecasts range from $66.61 to $98.00. On average, they expect AbbVie's stock price to reach $86.33 in the next year. This suggests a possible upside of 1.1% from the stock's current price. View Analyst Price Targets for AbbVie.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

Media stories about ABBV stock have trended somewhat positive on Thursday, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. AbbVie earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for AbbVie.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Valeant Pharmaceuticals Intl (VRX) and AT&T (T).

AbbVie's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Artemis Investment Management LLP (0.07%), Hamlin Capital Management LLC (0.06%), Candriam Luxembourg S.C.A. (0.05%), Gateway Investment Advisers LLC (0.04%), Zurcher Kantonalbank Zurich Cantonalbank (0.04%) and Janney Montgomery Scott LLC (0.04%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Galibier Capital Management Ltd., Ambassador Advisors LLC, Candriam Luxembourg S.C.A., Commerzbank Aktiengesellschaft FI, Meag Munich Ergo Kapitalanlagegesellschaft MBH, OLD National Bancorp IN, TIAA FSB and Nisa Investment Advisors LLC. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Laura J Schumacher and Timothy J Richmond. View Insider Buying and Selling for AbbVie.

ABBV stock was purchased by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Zurcher Kantonalbank Zurich Cantonalbank, Artemis Investment Management LLP, CHURCHILL MANAGEMENT Corp, 6 Meridian, Rhenman & Partners Asset Management AB, Manning & Napier Group LLC and Red Spruce Capital LLC. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin and William J Chase. View Insider Buying and Selling for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $85.38.

AbbVie has a market capitalization of $126.27 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.View Additional Information About AbbVie.

The official website for AbbVie is http://www.abbvie.com/.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.